Publication
Subgroup specific structural variation across 1,000 medulloblastoma genomes
Downloadable Content
- Persistent URL
- Last modified
- 05/15/2025
- Type of Material
- Authors
- Language
- English
- Date
- 2012-08-02
- Publisher
- Nature Publishing Group
- Publication Version
- Copyright Statement
- © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
- Final Published Version (URL)
- Title of Journal or Parent Work
- ISSN
- 0028-0836
- Volume
- 488
- Issue
- 7409
- Start Page
- 49
- End Page
- 56
- Grant/Funding Information
- JK and SP were supported by a grant from the German Cancer Aid (109252).
- Canada's Michael Smith Genome Sciences Centre is supported by the BC Cancer Foundation.
- PAN was supported by a Restracomp Fellowship (Hospital for Sick Children) and is currently a Roman-Herzog Postdoctoral Fellow (Hertie Foundation).
- Salary support for LG was provided by the Ontario Institute for Cancer Research through funding provided by the Government of Ontario.
- JR is supported by The Children's Discovery Institute.
- Funding is acknowledged from the Pediatric Brain Tumour Foundation (MDT and JTR), and the National Institutes of Health (CA159859 to MDT, RWR, and BW), Genome Canada, Genome BC, Terry Fox Research Institute, Ontario Institute for Cancer Research, Pediatric Oncology Group Ontario, Funds from ‘The Family of Kathleen Lorette’ and the Clark H. Smith Brain Tumour Centre, Montreal Children’s Hospital Foundation, Hospital for Sick Children: Sonia and Arthur Labatt Brain Tumour Research Centre, Chief of Research Fund, Cancer Genetics Program, Garron Family Cancer Centre, B.R.A.I.N. Child, CIHR (grant # ATE-110814); the University of Toronto McLaughlin Centre, CIHR Institute of Cancer Research (grant # AT1 – 112286) and C17 through the Advancing Technology Innovation through Discovery competition (Project Title: The Canadian Pediatric Cancer Genome Consortium: Translating next-generation sequencing technologies into improved therapies for high-risk childhood cancer).
- MDT is the recipient of a CIHR Clinician-Scientist Phase II award, and was formerly a Sontag Distinguished Scholar with funds from the Sontag Foundation.
- Supplemental Material (URL)
- Abstract
- Medulloblastoma, the most common malignant paediatric brain tumour, is currently treated with nonspecific cytotoxic therapies including surgery, whole-brain radiation, and aggressive chemotherapy. As medulloblastoma exhibits marked intertumoural heterogeneity, with at least four distinct molecular variants, previous attempts to identify targets for therapy have been underpowered because of small samples sizes. Here we report somatic copy number aberrations (SCNAs) in 1,087 unique medulloblastomas. SCNAs are common in medulloblastoma, and are predominantly subgroup-enriched. The most common region of focal copy number gain is a tandem duplication of SNCAIP, a gene associated with Parkinson's disease, which is exquisitely restricted to Group 4α. Recurrent translocations of PVT1, including PVT1-MYC and PVT1-NDRG1, that arise through chromothripsis are restricted to Group 3. Numerous targetable SCNAs, including recurrent events targeting TGF-β signalling in Group 3, and NF-κB signalling in Group 4, suggest future avenues for rational, targeted therapy. © 2012 Macmillan Publishers Limited. All rights reserved.
- Author Notes
- Keywords
- Research Categories
- Health Sciences, Oncology
- Health Sciences, Medicine and Surgery
- Biology, Neuroscience
- Biology, General
Tools
- Download Item
- Contact Us
-
Citation Management Tools
Relations
- In Collection:
Items
| Thumbnail | Title | File Description | Date Uploaded | Visibility | Actions |
|---|---|---|---|---|---|
|
|
Publication File - s9cm1.pdf | Primary Content | 2025-03-15 | Public | Download |